An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

Sponsor

Janssen Research & Development, LLC (Industry)

Overall Status

Completed

CT.gov ID

NCT01273389

Collaborator

(none)

Enrollment

Locations

Arms

Duration (Months)

1.1

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).

Condition or Disease	Intervention/Treatment	Phase
Lupus Nephritis	Drug: CNTO 136 Drug: Placebo	Phase 2

Detailed Description

This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double-blind (neither investigator nor the patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), parallel group (each group of patients will be treated at the same time) study of CNTO 136 in patients with active LN. The study consists of 3 phases, ie, the screening phase (approximately 8 weeks prior randomization), treatment phase (24 weeks), and the follow up phase (through week 40). An 8 week run-in period will be used to establish the stability of baseline renal parameters prior to randomization and the first study medication. The eligible patients will be randomly assigned in a 5:1 ratio to receive 1 of 2 treatment groups in the treatment phase: Group 1: CNTO 136 10 mg/kg intravenous (IV), at Weeks 0, 4, 8, 12, 16, 20, 24; and Group 2: Placebo infusion, IV, at Weeks 0, 4, 8, 12, 16, 20, 24. Patients' medication regimen for LN may be adjusted from the Week 24 visit and afterwards. Safety evaluations for adverse events, infections, clinical laboratory tests, electrocardiogram, vital signs, physical examination and skin evaluations will be performed throughout the study. The follow up phase or the end of study will be the Week 40 visit for the last patient randomized, or, in the event that the last patient randomized withdraws from the study early, the end of study is defined as the date of the last visit of the last patient participating in the study.

Study Design

Study Type:

Interventional

Actual Enrollment :

25 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Care Provider, Investigator)

Primary Purpose:

Treatment

Official Title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis

Study Start Date :

Aug 1, 2011

Actual Primary Completion Date :

Sep 1, 2013

Actual Study Completion Date :

Sep 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Experimental: CNTO 136 CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.	Drug: CNTO 136 Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
Placebo Comparator: Placebo	Drug: Placebo Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.

Arm

Intervention/Treatment

Experimental: CNTO 136

CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.

Drug: CNTO 136

Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.

Placebo Comparator: Placebo

Drug: Placebo

Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.

Outcome Measures

Primary Outcome Measures

Number of patients with reduction in proteinuria (measurement of total urine protein greater than 0.5 g/24-hours, or a urine protein to creatinine ratio greater than 0.5 mg/mg) [Baseline to Week 24]
It is measured as the percentage in reduction of proteinuria from baseline to Week 24.

Secondary Outcome Measures

Number of patients with a reduction from baseline in proteinuria by at least 50% [Up to Week 24]
It is measured as the proportion of patients with a reduction from baseline in proteinuria by at least 50% at any time through Week 24.
Number of patients with a meaningful reduction in proteinuria [Up to Week 24]
It is measured as the proportion of patients with meaningful reduction of proteinuria at any time through Week 24.
Number of patients with no worsening in Glomerular Filtration Rate (GFR) [Up to Week 24]
It is measured as the proportion of patients with no worsening in GFR at any time through Week 24.
Patient's Global Assessment of Disease Activity [Up to Week 24]
The Patient's Global Assessment of Disease Activity will be recorded on a visual analogue scale (VAS) (0 to 10 cm).
Physician's Global Assessment of Disease Activity [Up to Week 24]
The Physician's Global Assessment of Disease Activity will be recorded on a visual analogue scale (VAS) (0 to 10 cm).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of Systemic lupus erythematosus (SLE), and biopsy-proven International Society of Nephrology/Renal Pathology Society Class III or IV lupus glomerulonephritis within approximately 14 months prior to randomization
Persistently active nephritis defined as, proteinuria greater than 0.5g/day as determined by measurement of total urine protein less than 0.5 g/24- hours or a urine Protein/Creatinine (P/C) ratio greater than 0.5 (mg/mg) in a timed collection of 12 or more hours, for 2 months or more prior to the first administration of study medication and observed during at least 2 visits conducted 1 week apart during the screening period
Active Class III or Class IV lupus nephritis determined by recent biopsy within approximately 6 months prior to screening or at least 1 of the following 3 criteria: hematuria (blood in urine), anti-DNA positivity, or low C3 or C4 complement levels
Stable immunosuppression for at least 9 weeks prior to the first administration of study medication consisting of MMF 1-3 g/day (or equivalent dose of MPA) with/without corticosteroids up to prednisone equivalent of 20 mg/day, or azathioprine 1-3 mg/kg/day with/without corticosteroids up to prednisone equivalent of 20 mg/day
Stable dose of angiotensin-converting enzyme (ACE) inhibitor/angiotensin II receptor blocker (ARB) for at least 9 weeks prior to the first administration of study medication
If using oral corticosteroids, must be on a stable dose equivalent to 20 mg/day or less of prednisone for at least 9 weeks prior to the first administration of study medication

Exclusion Criteria:

Cyclophosphamide use within 3 months of randomization
B-cell depletion therapy within 6 months of screening, or evidence of persistent B-cell depletion at the time of screening
Greater than 50 percent glomerular sclerosis on renal biopsy
Serum creatinine > 2.5 mg/dL (SI: > 177 µmol/L)
White blood cell count < 3.5 x 10^{3 cells/µL (SI: < 3.5 x 10}9 cells/L) or neutrophils < 1.96 x 10^{3 cells/µL (SI: < 1.96 x 10}9 cells/L)
Platelets < 140 x 103 cells/ µL (SI: < 140 x 10^9 cells/L)

Contacts and Locations

Locations

	City	State	Country
1	Birmingham	Alabama	United States
2	Los Angeles	California	United States
3	Chicago	Illinois	United States
4	Lake Success	New York	United States
5	Columbus	Ohio	United States
6	Duncansville	Pennsylvania	United States
7	Chattanooga	Tennessee	United States
8	Carrollton	Texas	United States
9	Brussels		Belgium
10	Leuven		Belgium
11	Roeselare		Belgium
12	Guadalajara, Jalisco		Mexico
13	Guadalajara		Mexico
14	Mexico		Mexico
15	México		Mexico
16	Querétaro		Mexico
17	Rotterdam		Netherlands
18	Gdansk		Poland
19	Warszawa		Poland
20	Wroclaw		Poland
21	Bangkok		Thailand
22	Chiang Mai		Thailand